CORESTEMCHEMON Inc.

As of June 30, 2026, CORESTEMCHEMON Inc. carries a market capitalization of 104.13B, placing it among publicly traded companies globally. Its enterprise value stands at 137.34B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, CORESTEMCHEMON Inc. has 48.10M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 4.78, and the price-to-book ratio stands at 2.35.

These figures are as of June 30, 2026. The EV/Sales ratio of 7.51 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 137.34B versus a market cap of 104.13B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, CORESTEMCHEMON Inc. maintains a current ratio of 0.27, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 84.80, indicating elevated leverage, while an interest coverage ratio of -19.54 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, CORESTEMCHEMON Inc. posted a negative return on equity (ROE) of -61.95, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -25.49, reflecting losses generated across the asset base. The company generates approximately 54.64M in revenue per employee across its workforce of 334.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 109.39 indicates how many times CORESTEMCHEMON Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, CORESTEMCHEMON Inc. recorded an income tax benefit of -26.44M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -27.83B and -27.81B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, CORESTEMCHEMON Inc.'s stock has declined approximately 5.11% over the past 52 weeks. The 50-day moving average sits at 2,103.50, while the 200-day moving average is 2,532.48.

Over the twelve months ended June 30, 2026, CORESTEMCHEMON Inc. generated 18.29B in revenue and converted that into -27.81B in net income, yielding earnings per share of -689.21. EBITDA reached -16.96B, while operating income came in at -20.84B.

As of June 30, 2026, CORESTEMCHEMON Inc. holds 4.44B in cash and equivalents against 37.65B in total debt, resulting in a net debt position of 32.28B. Total book value stands at 44.40B, with working capital of -31.15B providing operational flexibility.

CORESTEMCHEMON Inc. produced -10.01B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.38B in capital expenditures, free cash flow totaled -11.39B - equivalent to -282.29 per share.

Over the twelve months ended June 30, 2026, CORESTEMCHEMON Inc. posted a gross margin of -26.51, reflecting its pricing power and cost economics. The operating margin of -113.93 and net profit margin of -152.02 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -13.04: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -7.86, meaning CORESTEMCHEMON Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

CORESTEMCHEMON Inc.'s most recent stock split took place on September 17, 2025 with a 13:16 split ratio.

As of June 30, 2026, CORESTEMCHEMON Inc. has an Altman Z-Score of -1.56, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.